Modeling Stress-precipitated Smoking Behavior for Medication Development

Yale University

Status and phase

Completed

Phase 2

Conditions

Smoking

Treatments

Drug: guanfacine

Drug: placebo

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00773357

RL1DA024857 (U.S. NIH Grant/Contract)

0808004163

P50DA033945 (U.S. NIH Grant/Contract)

U54AA027989 (U.S. NIH Grant/Contract)

P01AA027473 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to examine whether guanfacine will attenuate the ability of stress to precipitate smoking lapse behavior in treatment seeking and non-treatment seeking daily smokers.

Enrollment

100 patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

ages 18-60
able to read and write in English
smokers

Exclusion criteria

any significant current medical conditions that would contraindicate smoking
current Diagnostic and Statistical Manual IV (DSM-IV) abuse or dependence of other substances, other than nicotine (or caffeine) dependence
positive test result at intake appointments on urine drug screens conducted for opiates, cocaine, or benzodiazepines
women who are pregnant or nursing
suicidal, homicidal or evidence of severe mental illness
participants prescribed any psychotropic drug in the 30 days prior to study enrollment
blood donation within the past 6 weeks
participants who have engaged in a quit attempt in the past 3 months
specific exclusions for administration of guanfacine not already specified include: Hypotensive individuals with sitting blood pressure below 90/50 mmHG; EKG evidence at baseline screening of any clinically significant conduction abnormalities, including a Bazett's corrected QT interval (QTc) >450 msec for men and QTc>470 msec for women; known intolerance for guanfacine